- Home
- Automated
- List of product information
- BAXTER-LACTATED RINGER’S INJECTION USP [SIN16604P]
BAXTER-LACTATED RINGER’S INJECTION USP [SIN16604P]
Active ingredients: BAXTER-LACTATED RINGER’S INJECTION USP
Last updated 26 October 2025
Product Info
BAXTER-LACTATED RINGER’S INJECTION USP
[SIN16604P]
Product information
Active Ingredient and Strength | CALCIUM CHLORIDE DIHYDRATE - 20 MG PER 100 ML |
Dosage Form | INFUSION, SOLUTION |
Manufacturer and Country | BAXTER HEALTHCARE PHILIPPINES, INC - PHILIPPINES |
Registration Number | SIN16604P |
Licence Holder | BAXTER HEALTHCARE (ASIA) PTE LTD |
Forensic Classification | GENERAL SALE LIST |
Anatomical Therapeutic Chemical (ATC) code | B05BB01 |
INDICATIONS AND USAGE
Lactated Ringer’s Injection, USP is indicated as a source of water and electrolytes or as an alkalinizing agent.
DOSAGE AND ADMINISTRATION
Important Administration Instructions
Lactated Ringer’s Injection, USP is intended for intravenous administration using sterile equipment.
Do not connect flexible plastic containers in series in order to avoid air embolism due to possible residual air contained in the primary container.
Set the vent to the closed position on a vented intravenous administration set to prevent air embolism.
Use a dedicated line without any connections to avoid air embolism.
Do not pressurize intravenous solutions contained in flexible plastic containers to increase flow rates in order to avoid air embolism due to incomplete evacuation of residual air in the container.
Prior to infusion, visually inspect the solution for particulate matter and discoloration. The solution should be clear and there should be no precipitates. Do not administer unless solution is clear, and container is undamaged.
Do not administer Lactated Ringer’s Injection, USP simultaneously with citrate anticoagulated/preserved blood through the same administration set because of the likelihood of coagulation precipitated by the calcium content of Lactated Ringer’s Injection, USP.
Dosing Information
The choice of product, dosage, volume, rate, and duration of administration is dependent upon the age, weight and clinical condition of the patient and concomitant therapy, and administration should be determined by a physician experienced in intravenous fluid therapy.
Introduction of Additives
Additives may be incompatible.
Evaluate all additions to the plastic container for compatibility and stability of the resulting preparation. Consult with a pharmacist, if available.
Ceftriaxone is known to be incompatible with Lactated Ringer’s Injection, USP due to precipitate formation. Ceftriaxone must not be mixed with Lactated Ringer’s Injection, USP. If, in the informed judgment of the physician, it is deemed advisable to introduce additives, use aseptic technique. Mix thoroughly when additives have been introduced. After addition, if there is a discoloration and/or the appearance of precipitates, insoluble complexes or crystals, do not use. Do not store solutions containing additives. Use content immediately after opening the container. Discard any unused portion.
CONTRAINDICATIONS
Lactated Ringer’s Injection, USP is contraindicated in:
Newborns (≤28 days of age) receiving concomitant treatment with ceftriaxone, even if separate infusion lines are used due to the risk of fatal ceftriaxone-calcium salt precipitation in the neonate’s bloodstream.
Patients older than 28 days, including adults, administered ceftriaxone simultaneously through the same infusion line (e.g., via a Y-connector). If the same infusion line is used for sequential administration, the line must be thoroughly flushed between infusions with a compatible fluid.
Patients with known hypersensitivity to sodium lactate (see WARNINGS – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information).